D-0400-2024 Class II Terminated

Recalled by SCA Pharmaceuticals, LLC — Windsor, CT

FDA drug recall D-0400-2024 was initiated by SCA Pharmaceuticals, LLC on Nov 9, 2023 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Aug 27, 2024). Affected quantity: 412 cassettes.

Recall Details

Product Type
Drugs
Report Date
Apr 3, 2024
Initiation Date
Nov 9, 2023
Termination Date
Aug 27, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
412 cassettes

Product Description

fentaNYL 500 mcg/100 mL, Bupivacaine HCl 0.04% in 0.9% Sodium Chloride 100 mL Injection (fentaNYL Concentration = 5 mcg/mL), EPIDURAL USE ONLY, 100 mL Yellow CADD Cassette, Rx only, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT 06095, NDC 70004-0289-64, Bar Code 70004028964

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

Nationwide in the USA

Code Information

Lot #: 1223049261, Exp 12/25/23; 1223049724, Exp 01/11/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0400-2024
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0400-2024. Report a data issue: hello@regdatalab.com.